Studies involving additional RET MKIs, such as sorafenib [124], lenvatinib [34], and alectinib [125], also led to objective responses in RET-altered NSCLC, although with limited activity and prohibitive toxicity profiles [126]. This evidence concerns the gene RET and non-small cell lung carcinoma.